• Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 159.74 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.85
▲ +0.15 (4.05%)

This chart shows the closing price for PULM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pulmatrix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PULM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PULM

Analyst Price Target is $10.00
▲ +159.74% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Pulmatrix in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 159.74% upside from the last price of $3.85.

This chart shows the closing price for PULM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Pulmatrix. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/30/2022HC WainwrightReiterated RatingBuy$5.00 ➝ $10.00Medium
4/13/2021HC WainwrightLower TargetBuy$200.00 ➝ $100.00High
9/24/2020HC WainwrightReiterated RatingBuy$200.00Medium
11/10/2019HC WainwrightReiterated RatingBuy$200.00Medium
4/16/2019HC WainwrightReiterated RatingBuyMedium
11/19/2018HC WainwrightReiterated RatingBuyHigh
3/16/2018HC WainwrightLower TargetBuy$600.00Medium
2/9/2018HC WainwrightInitiated CoverageBuy ➝ Buy$1,000.00High
(Data available from 12/5/2017 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/8/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/7/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/6/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/6/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/5/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/5/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Pulmatrix logo
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $3.85
Low: $3.67
High: $3.94

50 Day Range

MA: $3.60
Low: $3.20
High: $4.06

52 Week Range

Now: $3.85
Low: $3.16
High: $15.60

Volume

40,800 shs

Average Volume

59,713 shs

Market Capitalization

$14.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Pulmatrix?

The following equities research analysts have issued reports on Pulmatrix in the last year: HC Wainwright, and StockNews.com.
View the latest analyst ratings for PULM.

What is the current price target for Pulmatrix?

1 Wall Street analysts have set twelve-month price targets for Pulmatrix in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 159.7%. HC Wainwright has the highest price target set, predicting PULM will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for Pulmatrix in the next year.
View the latest price targets for PULM.

What is the current consensus analyst rating for Pulmatrix?

Pulmatrix currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PULM will outperform the market and that investors should add to their positions of Pulmatrix.
View the latest ratings for PULM.

What other companies compete with Pulmatrix?

How do I contact Pulmatrix's investor relations team?

Pulmatrix's physical mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company's listed phone number is (781) 357-2333 and its investor relations email address is [email protected] The official website for Pulmatrix is www.pulmatrix.com. Learn More about contacing Pulmatrix investor relations.